Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Summary: A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

Medications designed to treat diabetes by lowering blood sugar levels, like Ozempic, continue to turn up added benefits, and ...

New research suggests that GLP-1 drugs like Ozempic and Wegovy, commonly used for diabetes and weight loss, may also reduce the risk of Alzheimer's disease and dementia.

Semaglutide — the powerful ingredient behind Wegovy and Ozempic — has long been hailed ... seems to be promising in reducing the risk of Alzheimer's disease and related dementias (ADRD)'.

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

In an April 14 announcement, the FDA stated that Novo Nordisk — manufacturer of Ozempic and Wegovy — notified the agency that ...

Ozempic may be known for weight loss, but new studies reveal it could also protect brain health and lower your risk of dementia and Alzheimer’s.

Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...